Strengths and weaknesses of ‘real-world’ studies involving non-vitamin K antagonist oral anticoagulants
Open Access
- 21 April 2018
- journal article
- research article
- Published by BMJ in Open Heart
- Vol. 5 (1), e000788
- https://doi.org/10.1136/openhrt-2018-000788
Abstract
Randomised controlled trials (RCTs) provide the reference standard for comparing the efficacy of one therapy or intervention with another. However, RCTs have restrictive inclusion and exclusion criteria; thus, they are not fully representative of an unselected real-world population. Real-world evidence (RWE) studies encompass a wide range of research methodologies and data sources and can be broadly categorised as non-interventional studies, patient registries, claims database studies, patient surveys and electronic health record studies. If appropriately designed, RWE studies include a patient population that is far more representative of unselected patient populations than those of RCTs, but they do not provide a robust basis for comparing treatment strategies. RWE studies can have very large sample sizes, can provide information on treatments in patient groups that are usually excluded from RCTs, are generally less expensive and quicker than RCTs, and can assess a broad range of outcomes. Limitations of RWE studies can include low internal validity, lack of quality control surrounding data collection and susceptibility to multiple sources of bias for comparing outcomes. RWE studies can complement the findings from RCTs by providing valuable information on treatment practices and patient characteristics among unselected patients. This information is necessary to guide treatment decisions and for reimbursement and payment decisions. RWE studies have been extensively applied in the postmarketing approval assessment of non-vitamin K antagonist oral anticoagulants since 2010. However, the benefits, costs, limitations and methodological challenges associated with the different types of RWE must be considered carefully when interpreting the findings.Keywords
Funding Information
- Bayer AG
This publication has 70 references indexed in Scilit:
- Risk Profiles and Antithrombotic Treatment of Patients Newly Diagnosed with Atrial Fibrillation at Risk of Stroke: Perspectives from the International, Observational, Prospective GARFIELD RegistryPLOS ONE, 2013
- Dabigatran use in Danish atrial fibrillation patients in 2011: a nationwide studyBMJ Open, 2013
- Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research DatabaseBMJ Open, 2012
- Apixaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2011
- The Danish National Patient RegisterScandinavian Journal of Public Health, 2011
- The Danish Civil Registration SystemScandinavian Journal of Public Health, 2011
- The Danish National Prescription RegistryScandinavian Journal of Public Health, 2011
- Written informed consent and selection bias in observational studies using medical records: systematic reviewBMJ, 2009
- Study Design, Precision, and Validity in Observational StudiesJournal of Palliative Medicine, 2009
- Pharmacoeconomic Evaluation in the Real WorldPharmacoEconomics, 1999